Sign in
Taking people in United StatesPhase 2

Descartes-08 for adults with antisynthetase syndrome and dermatomyositis muscle inflammation

Tests Descartes-08 against placebo in adults with antisynthetase syndrome or dermatomyositis.

Key facts

Who runs it
Cartesian Therapeutics
Where
Austin, Boston, Chapel Hill, and Orange, United StatesSee the 4 sites
Trial code
Registry title
Descartes-08 in Autoantibody Myositis
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
28 Apr 2026
Expected to end
May 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Descartes-08
  • Placebo
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dermatomyositis or antisynthetase syndrome that affects the muscles and/or skin. Their disease has not responded to standard therapy, or they could not tolerate it. Each person gets either Descartes-08 or a placebo.

Age
18 Years and older
Sex
All
Disease stage
Confirmed dermatomyositis (probability score ≥55% on the 2017 EULAR/ACR criteria) or antisynthetase syndrome (ACR/EULAR criteria). The disease must involve the muscles and/or skin. Blood, kidney, liver and lung function must be adequate (SpO₂ ≥92% on room air).
Earlier treatment
Disease did not respond to standard therapy, or the person could not tolerate it. Stable background immunosuppressive therapy for ≥8 weeks. No recent use of banned immune-suppressing drugs, biologics or study drugs, and no live vaccine within 4 weeks.

Main reasons for not taking part

  • Lung disease (ILD) only, without muscle or skin involvement, or ILD that needs oxygen, severe lung problems (FVC ≤45%, DLCO ≤40%) or pulmonary hypertension
  • Severe permanent muscle damage or advanced weakness, such as needing a wheelchair
  • Other inflammatory muscle diseases, or other severe autoimmune, heart, lung or nerve-muscle diseases
  • Pregnancy or breastfeeding
  • Active or uncontrolled infections such as HBV, HCV, HIV or tuberculosis, inborn immune deficiency, or a past organ or bone marrow transplant

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Confirmed diagnosis of one of the following:; Dermatomyositis (DM): Probability score ≥55% on the 2017 EULAR/ACR (European Alliance of Associations of Rheumatology/ American College of Rheumatology) criteria for classification of dermatomyositis (corresponding to diagnosis of 'probable or definite' DM). OR Antisynthetase Syndrome (ASyS): Diagnosis based on ACR/EULAR Classification Criteria (1)."
  • Participants must have dermatomyositis or antisynthetase syndrome with muscle and/or skin involvement
  • Refractory or intolerance to standard therapy
  • Stable background immunosuppressive therapy for ≥8 weeks
  • Adequate hematologic, renal, hepatic, and pulmonary function (SpO₂ ≥92% on room air)
  • Informed consent, compliance with visits, contraception, and vaccinations required

Who cannot take part

  • Isolated interstitial lung disease (ILD) without muscle or skin involvement; Severe irreversible muscle damage or advanced weakness (e.g., wheelchair-bound); Interstitial lung disease (ILD) requiring oxygen, severe pulmonary impairment (FVC ≤45%, DLCO ≤40%), or pulmonary hypertension; Other inflammatory myopathies (PM, IMNM, IBM, cancer- or drug-induced myositis, overlap myositis except Sjögren's); Other severe neuromuscular, cardiac, pulmonary, or systemic autoimmune diseases requiring immunosuppression; Significant uncontrolled chronic illnesses or psychiatric conditions interfering with participation; Pregnancy or lactation; Recent use of prohibited immunosuppressants/biologics or investigational agents (per washout periods); Live vaccination within 4 weeks; History of primary immunodeficiency, organ or bone marrow transplant; Active or uncontrolled infections: HBV, HCV, HIV, tuberculosis, or recurrent/severe infections

Where in United States

  • National Neuromuscular Research InstituteAustin, United StatesContact: Cartesian TherapeuticsTaking people
  • Brigham and Women's HospitalBoston, United StatesContact: Cartesian TherapeuticsTaking people
  • University of North CarolinaChapel Hill, United StatesContact: Cartesian TherapeuticsTaking people
  • University of California IrvineOrange, United StatesContact: Cartesian TherapeuticsTaking people

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).

The 2 groups in the trial

  • Decartes-08Treatment being tested

    Treatment: Descartes-08

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome
Plain-language title
Descartes-08 for adults with antisynthetase syndrome and dermatomyositis muscle inflammationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
17 August 2026